Longevity Health Holdings Overview
Longevity Health Holdings (XAGE) has a ROE of 78.49%, above the sector sector average of -6.13%.
Get informed when a big investor buys or sells
+ Follow78.49%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for XAGE is 78.49%. That is above the sector sector average of -6.13%. Investors often review this figure alongside Longevity Health Holdings's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, XAGE currently prints 78.49% for ROE, while the sector average sits near -6.13%. That is roughly 1380.7% above the sector mean. Large gaps often invite a closer look at Longevity Health Holdings's growth, margins, and balance sheet.
Return on Equity shows how effectively Longevity Health Holdings converts resources into returns. At 78.49%, XAGE may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting XAGE's ROE (78.49%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
